Results 131 to 140 of about 685,816 (191)

CXCL13 Damages Blood Spinal Cord Barrier by Promoting RNF6/Sqstm1‐Ubiquitination Induced Autophagy in Experimental Allergic Encephalomyelitis

open access: yesAdvanced Science, EarlyView.
In multiple sclerosis, the disruption of the blood‐spinal cord barrier (BSCB) induced by CXCL13 facilitates the infiltration of inflammatory cells into the central nervous system, resulting in demyelination and neuronal injury. Mechanistically, the deleterious impact of CXCL13 on the BSCB is associated with a reduction in tight junction protein ...
Jingjing Han   +10 more
wiley   +1 more source

Correction: The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency. [PDF]

open access: yesMicrobiome
Chandrasekaran P   +19 more
europepmc   +1 more source

A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma

open access: yesAdvanced Science, EarlyView.
The TPC@OVA NPs are developed as dual‐functional nanomaterials combining phototherapy and immunotherapy for melanoma treatment. This system effectively ablates primary tumors, induces immunogenic cell death, promotes dendritic cell maturation, and enhances T cell activation.
Zhuang Fan   +6 more
wiley   +1 more source

MYC Binding Near Transcriptional End Sites Regulates Basal Gene Expression, Read‐Through Transcription, and Intragenic Contacts

open access: yesAdvanced Science, EarlyView.
MYC is a transcription factor (TF) that binds DNA near transcriptional start sites (TSSs) and within enhancer elements. Here, unappreciated sites of MYC binding in the vicinity of transcriptional end sites (TESs) of many genes in multiple cell types in association with numerous other TFs are described previously.
Huabo Wang   +5 more
wiley   +1 more source

Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice. [PDF]

open access: yesImmunotargets Ther
Gherardi L   +5 more
europepmc   +1 more source

Tumor Microenvironment Triggered In Situ Coagulation of Supramolecularly Engineered Platelets for Precise Tumor Embolization

open access: yesAdvanced Science, EarlyView.
Occlusion of tumor blood vessels represents a promising yet challenging approach in cancer treatment. Herein, supramolecularly engineered platelets conjugated with morphology‐transformable nanoparticles is developed for precise tumor embolization. The engineered platelets actively accumulate at tumor sites following induced blood vessel injury.
Junyan Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy